Uscom Ltd (ASX:UCM) founder, chairman and chief executive Rob Phillips speaks to Proactive Investors about the cardiovascular-pulmonary medical device producer's expanding global operations and product offering.
The company is obtaining final approvals to launch new products in Australia, China, Europe and the USA. Phillips explains, "what that will give us is a diversified suite of novel products that are sector-leading and quite revolutionary in cardiac output, vascular assessment, and in pulmonary/respiratory... our products basically assist the management and care of patients that have diseases which kill 75% of the world's population, so they are massively relevant. Heart failure, sepsis, asthma, COPD, hypertension; these are diseases that are in our space, so we've got a really strong underwritten clinical need."
"We've been growing at 30-40% per annum, and that's with one product. And we're on the cusp now of releasing seven new products into global markets... we're looking forward to the next two to three years, and taking investors with us on that journey, because we will transform from being a small Australian biotech to being a significant international biotechnology company," says Phillips.